INOVIO Reports Fourth Quarter 2021 and Year-End Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Inovio Pharmaceuticals (INO) PT Lowered to $30 at Oppenheimer
March 2, 2022 12:56 PM ESTOppenheimer analyst Hartaj Singh lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $30.00 (from $35.00) while maintaining an Outperform rating after the company provided a business and pipeline update to investors on 3/1.
The analyst commented, "While the company reported steady progress, the... More
Inovio Pharma (INO) Misses Q4 EPS by $1.13
March 1, 2022 4:33 PM ESTInovio Pharma (NASDAQ: INO) reported Q4 EPS of ($1.45), $1.13 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $1.77 million versus the consensus estimate of $2.84 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
... More